Search

Introduction: The categorization of mature B cell neoplasms (MBN) infiltrating blood and bone marrow are met with difficulties. The inclusion of CD148 and CD180 in the routine flow cytometry/FCM panels has been suggested to refine the diagnosis. We studied the discriminatory ability of CD148 and CD180 median fluorescence intensity(MFI), CD148/CD180 ratio and their expression relative to T cells (CD148ab/T, CD180ab/T), neutrophils (CD148ab/gr, CD180ab/gr) and normal B cells (CD148ab/n, CD180ab/n) in the differentiation of mature B cell neoplasms (MBN) especially non‐chronic lymphocytic leukaemia (CLL). Methodology: The flow cytometric (FCM) expression of CD148 and CD180 was studied prospectively in 102 patients (non‐CLL; n = 72); diagnosed by a comprehensive panel of immunophenotypic and cytogenetic studies. The MFI and ratios were statistically compared across MBNs by Mann‐Whitney U test. Cut‐off values, sensitivity and specificity were calculated for significant parameters by receiver operator characteristic curve. Results: CD180MFI > 4.35 showed 100% sensitivity and 90.9% specificity for a diagnosis of marginal zone lymphoma (MZL) while, CD148/180 > 5.15 was 100% specific and 81.8% sensitive for lymphoplasmacytic lymphoma. CD148ab/T(>4.3; 100% specificity, 83.4% sensitivity) and CD148ab/gr(>1.1; 100% sensitivity, 90% sensitivity) were useful for differentiating blastoid‐mantle cell lymphoma/MCL from diffuse large B cell lymphoma; while CD148MFI (≥20.25), CD148ab/T(>3.35) and CD148ab/gr(>0.95) showed >90% specificity and sensitivity for distinguishing MCL from CLL. Pairwise analysis also showed a good discriminant function of various parameters for distinguishing SMZL from other MBNs like FL, MCL as well as CLL. Conclusions: The current study shows an excellent utility of CD148MFI, CD180MFI, their ratio and relative expression levels in the subcategorization of immunophenotypically related MBNs. [ABSTRACT FROM AUTHOR]

The article describes the case of a previously one-year, three-month-old child with a history of intermittent low-grade fever relieved by antipyretics for one month. Topics discussed include findings on clinical examination, factor which raised the possibility of acute monocytic leukemia (AMoL), and laboratory results which led to the diagnosis of histiocytic sarcoma (HS).

The article presents a case study of 33-year-old man presented with pain abdomen, loss of appetite, weight loss, and generalized lymphadenopathy for three months. It mentions deviation from well-established investigative algorithms may lead to unnecessary diagnostic confusion with potentially serious consequences; and also mentions high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH) showing discordant PB morphology.

Background: Chronic myeloid leukemia (CML) is a hematopoietic stem cell (SC) neoplasm diagnosed by the demonstration of t(9;22)(BCR‐ABL1) fusion gene. We performed a flow cytometric assay to identify CD26+ CML leukemic stem cells (LSCs) for its value as a standalone diagnostic investigation for CML and its utility for detection of residual disease in CML patients on therapy. Methods: Patients with clinical suspicion of CML/CML on follow‐up were included, and peripheral (PB) and/or bone marrow (BM) samples were utilized for flow cytometric analysis. PB and/or BM of patients with diseases other than CML were used as controls. A pre‐titrated antibody cocktail containing CD45, CD34, CD38, and CD26 MoABs was used. Results: A total of 104 samples (63 PB and 41 BM) from 64 patients [suspected CML (n = 30), CML on follow‐up (n = 15), and non‐CML (n = 19)] were tested. CD26+ LSCs were identified in all patients with a confirmed diagnosis of CML (median = 0.07 (range 0.002%–26.79%)). None of the patients in the control group (non‐CML) and follow‐up patients with negative reverse transcriptase‐polymerase chain reaction (RT‐PCR) results showed the presence of CD26+ LSCs. Also, there was a strong correlation between CD26+ CML LSCs in the PB and BM (r =.917). Conclusion: Flow cytometric identification of CD26+ LSCs in the peripheral blood can be a cheap, rapid, robust, and potential diagnostic tool for the diagnosis of CML compared to available testing methods. It is irrespective of BCR‐ABL1 transcript type, and its role in residual disease monitoring needs thorough investigation. [ABSTRACT FROM AUTHOR]

Background: Immunomagnetic cell sorting (IMCS) is a preferred technique for the enrichment of plasma cells (PC) before fluorescence in situ hybridization (FISH). Here, we share our real‐world experience regarding the success rate of IMCS, its limitations, and the utility of alternate sources to obtain a successful FISH in various PC disorders. Materials and Methods: A retrospective analysis was performed in patients with a PC neoplasm, who underwent bone marrow (BM) examination, and FISH testing over 30 months. In all cases with an unsuccessful IMCS, an attempt was made to identify the cause of failure. Results: Immunomagnetic cell sorting of PCs was successful in 395/450 cases (87.8%; 77/98 cases (78.6%) with <10% PCs and 318/352 (90.3%) with ≥10% PCs in BM aspirate; P =.003). Among cases with unsuccessful IMCS (<10% PCs; n = 21 and ≥10% PCs; n = 34), an alternate source could be used successfully in 34 (62%) patients and includes air‐dried trephine biopsy imprint smears (n = 28) with aggregates or sheets of PCs, fine‐needle aspiration smears/biopsy from plasmacytoma (n = 5), and ascitic fluid (n = 1). 284/395 (71.9%) patients with successful IMCS and all 34 cases with an alternate source of PCs showed at least one cytogenetic abnormality on four‐probe FISH. Conclusion: Variations in the sample quality together with significant variation in the number of PCs between BM aspirate and the trephine biopsy imprint smears/biopsy reduce the success rate of IMCS in a real‐world scenario and necessitate utilization of patient‐specific alternate sources of PCs like a trephine biopsy imprint or cytology smears from extramedullary sources for successful FISH testing in PC neoplasms. [ABSTRACT FROM AUTHOR]

The article focuses on utility of fluorescence in situ hybridization testing in patients has suspected of myelodysplastic syndrome (MDS) or myelodysplastic syndrome/myeloproliferative neoplasm overlap (MDS/MPN) is limited in the absence of significant morphological dysplasia. Topics include the MDS/MPN are clonal disorders of hematopoietic stem cells has characterized by progression to acute myeloid leukemia, and the cytogenetic information is essential for their prognostic assessment.

The article discusses that genetic abnormalities have significantly contributed to disease stratification in B‐ALL. It mentions the detection of iAMP21 can easily be achieved by multiplex ligation‐dependent probe amplification (MLPA); and also mentions that iAMP21 is reported to be a primary genetic event in B‐ALL subgroup arising due to complex structural rearrangements and is associated with a dismal outcome.